Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials

Frederic Baron, MD PhD, Marian Stevens-Kroef, PhD, Giovanna Meloni, MD, Petra Muus, MD PhD, Jean-Pierre Marie, MD, Constantijn J.M. Halkes, MD PhD, Xavier Thomas, MD PhD, Radovan Vrhovac, MD PhD, Giorgina Specchia, MD, Francois Lefrere, Sr., MD, Simona Sica, Marco Mancini, MD, Adriano Venditti, MD, Anne Hagemeijer, MD, Joop H. Jansen, PhD, Sergio Amadori, MD, Theo de Witte, MD, Roelof Willemze, MD PhD, Stefan Suciu, PhD

Blood (2016) 128 (22): 2847.

https://doi.org/10.1182/blood.V128.22.2847.2847

Published: 2016

Journal Articles

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Blood (2016) 128 (22): 2288.

https://doi.org/10.1182/blood.V128.22.2288.2288

Published: 2016

Journal Articles

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Dominik L.D. Selleslag, MD, Stefan Suciu, Giovanna Meloni, MD, Petra Muus, MD PhD, Constantijn J.M. Halkes, MD PhD, Adriano Venditti, MD, Safaa M Ramadan, MD PhD, Hans Pruijt, MD PhD, Liv Meert, MSc, Marco Vignetti, MD, Jean-Pierre Marie, MD, Dominique Bron, MD PhD, Theo de Witte, MD, Sergio Amadori, MD, Roelof Willemze, MD PhD, Frederic Baron, MD PhD

Blood (2014) 124 (21): 3675.

https://doi.org/10.1182/blood.V124.21.3675.3675

Published: 2014

Journal Articles

Aberrant 5-Hydroxymethylcytosine Levels Correlate With Poor Overall Survival In Acute Myeloid Leukemia

Leonie I Kroeze, Mariam G Aslanyan, Arno van Rooij, Theresia N Koorenhof-Scheele, Marion Massop, Thomas Carell, Jan B Boezeman, Jean-Pierre Marie, MD, Constantijn J.M. Halkes, MD, PhD, Theo M. de Witte, MD, Gerwin Huls, Stefan Suciu, PhD, Ron Wevers, Bert A. van der Reijden, Joop H. Jansen, PhD

Blood (2013) 122 (21): 1261.

https://doi.org/10.1182/blood.V122.21.1261.1261

Published: 2013

Journal Articles

Prognostic Impact Of Body Mass Index (BMI) In Acute Myeloid Leukemia (AML)

Emmanuelle Kempf, Pierre Hirsch, Myriam Labopin, Christophe Marzac, MD, Jean-Yves Perrot, Françoise Isnard, MD, Jean-Pierre Marie, MD, Mohamad Mohty, MD, PhD, Ollivier Legrand, MD, PhD

Blood (2013) 122 (21): 2658.

https://doi.org/10.1182/blood.V122.21.2658.2658

Published: 2013

Journal Articles

Survival Improvement Of Secondary Acute Myeloid Leukemia Over Time: Experience From 962 Patients Included In 13 EORTC-Gimema-HOVON Leukemia Group Trials

Safaa M. Ramadan, MD, PhD, Stefan Suciu, PhD, Marian J.P.L. Stevens-Kroef, PhD, Roelof Willemze, MD, PhD, Sergio Amadori, Theo de Witte, MD, Bob Lowenberg, MD, PhD, Petra Muus, MD, PhD, Boris Labar, MD, PhD, Liv Meert, Gaetan de Schaetzen, Giovanna Meloni, MD, Giuseppe Leone, MD, Marco Vignetti, Franco Mandelli, MD, Frederic Baron, MD, PhD, Jean-Pierre Marie, MD

Blood (2013) 122 (21): 829.

https://doi.org/10.1182/blood.V122.21.829.829

Published: 2013

Journal Articles

Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Martin S Tallman, MD, Gary Schiller, MD, Denise Trone, Guy Gammon, MD, Stuart Goldberg, MD, Alexander E Perl, MD, Jean-Pierre Marie, MD, Giovanni Martinelli, Mark Levis, MD, PhD

Blood (2013) 122 (21): 494.

https://doi.org/10.1182/blood.V122.21.494.494

Published: 2013

Journal Articles

High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) During Induction and IL-2 Vs Observation After Consolidation/Autologous Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML): Final Report of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups on the Value of High Dose AraC

Blood (2011) 118 (21): 257.

https://doi.org/10.1182/blood.V118.21.257.257

Published: 2011

Journal Articles

Clofarabine in Combination with a Standard Remission Induction Regimen (AraC and idarubicin) in Patients with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS):Phase I Results of An Ongoing Phase I/II Study of the EORTC-LG and GIMEMA(EORTC GIMEMA 06061/AML-14A trial)

Roelof Willemze, MD, PhD, Petra Muus, MD, PhD, Stijn J.M. Halkes, Giovanna Meloni, MD, Stefan Suciu, Liv Meert, Jocelyne Flament, Matthias Karrasch, Marco Vignetti, Sergio Amadori, MD, Theo M. de Witte, MD, Jean-Pierre Marie, MD

Blood (2011) 118 (21): 2610.

https://doi.org/10.1182/blood.V118.21.2610.2610

Published: 2011

Journal Articles

ABC Proteins Activity Remains An Independent Prognostic Factor In 206 AML When Compared to Other Molecular Markers, FLT3, NPM1, CEBPα, and BAALC

Pierre Hirsch, Ruoping Tang, Christophe Marzac, Jean-Yves Perrot, Fanny Fava, Chantal Bernard, Jean-Pierre Marie, MD, Ollivier Legrand

Blood (2010) 116 (21): 1698.

https://doi.org/10.1182/blood.V116.21.1698.1698

Published: 2010

Journal Articles

Value of Low Dose IL-2 as Maintenance Following Consolidation Treatment or Autologous Transplantation in Acute Myelogenous Leukemia (AML) Patients Aged 15-60 Years Who Reached CR After High Dose (HD-AraC) Vs Standard Dose (SD-AraC) Cytosine Arabinoside During Induction: Results of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups.

Blood (2009) 114 (22): 791.

https://doi.org/10.1182/blood.V114.22.791.791

Published: 2009

Journal Articles

A Novel Mechanism of Action of Rivaroxaban: Inhibition of Monocyte and Macrophage Procoagulant Activity and Consequence On Inflammatory Process.

Marc Laurent, Remi Varin, Ulrich Joimel, Hong Li, He Lu, Emmanuel Blot, Shahsultan Mirshahi, Lionel Cazin, Jean Chidiac, Jean-Pierre Marie, MD, Jeannette Soria, Claudine Soria

Blood (2009) 114 (22): 3124.

https://doi.org/10.1182/blood.V114.22.3124.3124

Published: 2009

Journal Articles

An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML).

Ollivier Legrand, MD, Maria B. Vidriales, MD, Xavier Thomas, MD, Charles Dumontet, MD, Anne Vekhoff, MD, Rodica Morariu-Zamfir, MD, John Lambert, MD, Jesus F. San Miguel, MD, Jean-Pierre Marie, MD

Blood (2007) 110 (11): 1850.

https://doi.org/10.1182/blood.V110.11.1850.1850

Published: 2007

Journal Articles

Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with a Pediatric Protocol: Results of a Pilot Study.

Stephanie Haiat, MD, Anne Vekhoff, MD, Christophe Marzac, MD, OrsAnton Calendini, MD, Simona Lapusan, MD, Zora Marjanovic, MD, Bernard Rio, MD, Jean-Pierre Marie, MD, Ollivier Legrand, MD

Blood (2007) 110 (11): 2822.

https://doi.org/10.1182/blood.V110.11.2822.2822

Published: 2007

Journal Articles

Prognosis Value of Flt3 Internal Tandem Duplication and P-Glycoprotein Functionality, in 171 AML.

Christophe Marzac, MD, Irene Teyssandier, MD, Jean Yves Perrot, MD, Anne Marie Faussat, MD, Ruoping Tang, PhD, Nicole Casadevall, MD, PhD, Jean Pierre Marie, MD, PhD, Ollivier Legrand, MD, PhD

Blood (2005) 106 (11): 2375.

https://doi.org/10.1182/blood.V106.11.2375.2375

Published: 2005

Journal Articles

Is Consolidation and/or Maintenance Treatment a Standard Therapy in Elderly AML in First Complete Remission?.

Elise Corre, MD, Jean-Pierre Marie, MD, Ollivier Legrand, MD

Blood (2005) 106 (11): 2775.

https://doi.org/10.1182/blood.V106.11.2775.2775

Published: 2005

Journal Articles

Dexamethasone Versus Methyl-Prednisolone in Induction Therapy for Adult Acute Lymphoblastic (ALL) and Non-Hodgkin Lymphoma (NHL) Patients ≤ 60 Yrs Old: Final Results of the Eortc All-4 Phase III Trial.

Boris Labar, MD, PhD, Stefan Suciu, PhD, Petra Muus, MD, Roelof Willemze, MD, PhD, Jean-Pierre Marie, MD, Georges Fillet, MD, Zwi Berneman, MD, Branimir Jaksic, MDPhD, Walter Feremans, MD, Dominique Bron, MD, Henry Sinnige, MD, Martin Mistrik, MD, G. Vreugdenhil, MD, Robrecht De Bock, MD, Damir Nemet, MD, Caroline Gilotay, Theo de Witte, MDPhD, Sergio Amadori, MD

Blood (2005) 106 (11): 1834.

https://doi.org/10.1182/blood.V106.11.1834.1834

Published: 2005

Journal Articles

Early Diagnosis of Invasive Aspergillosis in Hematological Patients Using a PCR-ELISA Assay: A Prospective Validation.

Muriel Cornet, MD, Sandrine Katsahian, MD, Anne Vekhoff, MD, Vincent Levy, MD, PhD, Bernard Rio, MD, Jean-Pierre Marie, MD, PhD, Anne Bouvet, MD, PhD, Martine Florent, MD

Blood (2004) 104 (11): 3833.

https://doi.org/10.1182/blood.V104.11.3833.3833

Published: 2004

NARROW

Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Aberrant 5-Hydroxymethylcytosine Levels Correlate With Poor Overall Survival In Acute Myeloid Leukemia

Prognostic Impact Of Body Mass Index (BMI) In Acute Myeloid Leukemia (AML)

Survival Improvement Of Secondary Acute Myeloid Leukemia Over Time: Experience From 962 Patients Included In 13 EORTC-Gimema-HOVON Leukemia Group Trials

Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)

ABC Proteins Activity Remains An Independent Prognostic Factor In 206 AML When Compared to Other Molecular Markers, FLT3, NPM1, CEBPα, and BAALC

A Novel Mechanism of Action of Rivaroxaban: Inhibition of Monocyte and Macrophage Procoagulant Activity and Consequence On Inflammatory Process.

An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML).

Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with a Pediatric Protocol: Results of a Pilot Study.

Prognosis Value of Flt3 Internal Tandem Duplication and P-Glycoprotein Functionality, in 171 AML.

Is Consolidation and/or Maintenance Treatment a Standard Therapy in Elderly AML in First Complete Remission?.

Dexamethasone Versus Methyl-Prednisolone in Induction Therapy for Adult Acute Lymphoblastic (ALL) and Non-Hodgkin Lymphoma (NHL) Patients ≤ 60 Yrs Old: Final Results of the Eortc All-4 Phase III Trial.

Early Diagnosis of Invasive Aspergillosis in Hematological Patients Using a PCR-ELISA Assay: A Prospective Validation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only